This article was originally published in The Gray Sheet
Debt holder Amoco Technology Company converts a 7.9% note for $2.4 mil. plus $658,839 in interest into 428,532 shares of Quidel common stock at a $7.14 per share conversion price. The note was issued in 1990 and "would have become convertible at the option of Quidel in August of this year at the same conversion price," according to Quidel. The maker of rapid diagnostic tests announced the retirement of $4 mil. in 12% unsecured long-term debt earlier this month ("The Gray Sheet" July 19, p. 22). The firm says the two transactions increase shareholder equity by 72% over the March 31 level.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.